Cumberland Pharmaceuticals INC (CPIX) — SEC Filings

Overview

Cumberland Pharmaceuticals INC (CPIX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 23, 2026: Cumberland Pharmaceuticals Inc. filed a Definitive Proxy Statement (DEFA14A) on April 23, 2026. The filing includes various exhibits such as the proxy statement itself, and other materials related to shareholder matters. The company is headquartered in Nashville, TN.

Sentiment Summary

Across 34 filings, the sentiment breakdown is: 2 bearish, 32 neutral. The dominant filing sentiment for Cumberland Pharmaceuticals INC is neutral.

Filing Type Overview

Cumberland Pharmaceuticals INC (CPIX) has filed 23 8-K, 1 DEFA14A, 6 10-Q, 1 DEF 14A, 2 10-K, 1 SC 13G with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (34)

• 8-K Filing — 8-K · Apr 24, 2026
• Cumberland Pharmaceuticals Files Definitive Proxy Statement — DEFA14A · Apr 23, 2026 Risk: low
  Cumberland Pharmaceuticals Inc. filed a Definitive Proxy Statement (DEFA14A) on April 23, 2026. The filing includes various exhibits such as the proxy statement
• 8-K Filing — 8-K · Apr 23, 2026
• Cumberland Pharmaceuticals Enters Material Definitive Agreement — 8-K · Nov 24, 2025 Risk: medium
  On November 18, 2025, Cumberland Pharmaceuticals Inc. entered into a material definitive agreement, creating a direct financial obligation. The specific details
• Cumberland Pharma's Q3 Loss Widens, 9-Month Revenue Up 12.4% — 10-Q · Nov 7, 2025 Risk: high
  Cumberland Pharmaceuticals Inc. reported a net loss of $1,940,764 for the three months ended September 30, 2025, an increase from a net loss of $1,544,081 in th
• Cumberland Pharmaceuticals Files 8-K on Financials — 8-K · Nov 4, 2025 Risk: low
  Cumberland Pharmaceuticals Inc. filed an 8-K on November 4, 2025, reporting on its results of operations and financial condition. The filing includes financial
• Cumberland Pharmaceuticals Files 8-K: Other Events — 8-K · Oct 21, 2025 Risk: medium
  On October 21, 2025, Cumberland Pharmaceuticals Inc. filed a Form 8-K to report "Other Events." The filing does not contain specific details about the nature of
• Cumberland Pharma's Q2 Net Loss Widens to $1.1M Amid Revenue Dip — 10-Q · Aug 8, 2025 Risk: high
  Cumberland Pharmaceuticals Inc. reported a net loss of $1.1 million for the three months ended June 30, 2025, a significant increase from the $0.3 million net l
• Cumberland Pharmaceuticals Files 8-K on Financials — 8-K · Aug 5, 2025 Risk: low
  Cumberland Pharmaceuticals Inc. filed an 8-K on August 5, 2025, reporting on its results of operations and financial condition, as well as financial statements
• Cumberland Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 9, 2025 Risk: low
  Cumberland Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial performance and position as of Q
• Cumberland Pharmaceuticals Files 8-K — 8-K · May 6, 2025 Risk: low
  Cumberland Pharmaceuticals Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition, as well as financial statements and
• Cumberland Pharmaceuticals Files 8-K on Shareholder Votes — 8-K · Apr 28, 2025 Risk: low
  Cumberland Pharmaceuticals Inc. filed an 8-K on April 28, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain sp
• Cumberland Pharmaceuticals Files 8-K Report — 8-K · Mar 19, 2025 Risk: low
  On March 19, 2025, Cumberland Pharmaceuticals Inc. filed an 8-K report. The filing indicates that the company is located at 1600 West End Avenue, Suite 1300, Na
• Cumberland Pharmaceuticals Files 2025 Proxy Statement — DEF 14A · Mar 10, 2025 Risk: low
  Cumberland Pharmaceuticals Inc. filed its definitive proxy statement (DEF 14A) on March 10, 2025, for the fiscal year ending December 31, 2024. The filing provi
• Cumberland Pharmaceuticals Files 2024 10-K — 10-K · Mar 7, 2025 Risk: low
  Cumberland Pharmaceuticals Inc. filed its 2024 10-K on March 7, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Nashville, TN
• Cumberland Pharmaceuticals Files 8-K — 8-K · Mar 4, 2025 Risk: low
  Cumberland Pharmaceuticals Inc. filed an 8-K on March 4, 2025, reporting on its results of operations and financial condition. The filing includes financial sta
• Cumberland Pharmaceuticals Files 8-K Report — 8-K · Feb 19, 2025 Risk: low
  On February 19, 2025, Cumberland Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific transaction
• Cumberland Pharmaceuticals Files 8-K — 8-K · Feb 14, 2025 Risk: low
  Cumberland Pharmaceuticals Inc. filed an 8-K on February 14, 2025, reporting other events and financial statements. The filing does not contain specific financi
• Cumberland Pharmaceuticals Files 8-K Report — 8-K · Feb 4, 2025 Risk: low
  On February 4, 2025, Cumberland Pharmaceuticals Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific fin
• Cumberland Pharmaceuticals Files 8-K for Other Events — 8-K · Dec 9, 2024 Risk: medium
  Cumberland Pharmaceuticals Inc. filed an 8-K on December 9, 2024, to report "Other Events." The filing does not contain specific details about the nature of the
• Amneal Pharmaceuticals to Acquire Cumberland Pharmaceuticals — 8-K · Nov 12, 2024 Risk: medium
  Cumberland Pharmaceuticals Inc. announced on November 6, 2024, that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals LLC. The
• Cumberland Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Nov 8, 2024 Risk: medium
  Cumberland Pharmaceuticals Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for th
• Cumberland Pharmaceuticals Files 8-K on Financials — 8-K · Nov 7, 2024 Risk: low
  Cumberland Pharmaceuticals Inc. filed an 8-K on November 7, 2024, to report on its results of operations and financial condition, as well as to file financial s
• Amneal Pharmaceuticals to Acquire Cumberland Pharmaceuticals — 8-K · Nov 6, 2024 Risk: medium
  Cumberland Pharmaceuticals Inc. announced on November 6, 2024, that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals LLC. The
• Cumberland Pharmaceuticals Files 8-K — 8-K · Nov 4, 2024 Risk: medium
  Cumberland Pharmaceuticals Inc. filed an 8-K on November 4, 2024, to report other events. The filing does not contain specific details about the nature of these
• Cumberland Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 9, 2024 Risk: medium
  Cumberland Pharmaceuticals Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the sec
• Cumberland Pharmaceuticals Files 8-K on Financials — 8-K · Aug 6, 2024 Risk: low
  Cumberland Pharmaceuticals Inc. filed an 8-K on August 6, 2024, to report on its financial condition and results of operations. The filing includes financial st
• Cumberland Pharmaceuticals Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: low
  CUMBERLAND PHARMACEUTICALS INC (CPIX) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Cumberland Pharmaceuticals Inc. filed a 10-Q report for the
• Cumberland Pharmaceuticals Files 8-K on Financials — 8-K · May 7, 2024 Risk: low
  Cumberland Pharmaceuticals Inc. filed an 8-K on May 7, 2024, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and
• Cumberland Pharmaceuticals Files 8-K on Shareholder Vote Matters — 8-K · Apr 29, 2024 Risk: low
  Cumberland Pharmaceuticals Inc. filed an 8-K on April 29, 2024, to report on a submission of matters to a vote of security holders. The filing does not contain
• Cumberland Pharmaceuticals Files 8-K — 8-K · Mar 20, 2024 Risk: low
  Cumberland Pharmaceuticals Inc. filed an 8-K on March 20, 2024, to report other events and file financial statements and exhibits. The filing does not contain s
• Cumberland Pharmaceuticals Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 13, 2024 Risk: low
  CUMBERLAND PHARMACEUTICALS INC (CPIX) filed a Annual Report (10-K) with the SEC on March 13, 2024. Cumberland Pharmaceuticals Inc. filed its 2023 Form 10-K on M
• Cumberland Pharmaceuticals Files 8-K — 8-K · Mar 5, 2024 Risk: low
  Cumberland Pharmaceuticals Inc. filed an 8-K on March 5, 2024, to report on its results of operations and financial condition, as well as to file financial stat
• Cumberland Pharma CEO Kazimi Files SC 13G, Maintains Significant Stake — SC 13G · Feb 9, 2024 Risk: low
  A.J. Kazimi, the CEO of Cumberland Pharmaceuticals Inc., filed an Amendment No. 11 to Schedule 13G on February 9, 2024, indicating his beneficial ownership of t

Risk Profile

Risk Assessment: Of CPIX's 32 recent filings, 2 were flagged as high-risk, 8 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Cumberland Pharmaceuticals INC's most recent 10-Q filing (Nov 7, 2025):

• Revenue: $30,842,780
• Net Income: -$1,424,436
• EPS: N/A
• Debt-to-Equity: 1.55
• Cash Position: $15,196,745
• Operating Margin: -4.6%
• Total Assets: $65,898,560
• Total Debt: $40,097,856

Key Executives

• A.J. Kazimi

Industry Context

Cumberland Pharmaceuticals operates in the highly competitive pharmaceutical market, focusing on niche therapeutic areas. The industry is characterized by significant R&D investment, stringent regulatory oversight from bodies like the FDA, and reliance on product lifecycle management. Success hinges on effective commercialization of existing products and development of new ones, while managing manufacturing and supply chain complexities.

Top Tags

sec-filing (8) · 8-K (7) · financial-reporting (5) · regulatory-filing (4) · 10-Q (4) · Pharmaceuticals (3) · financial-results (3) · pharmaceuticals (3) · proxy-statement (2) · Biotech (2)

Key Numbers

• Net loss for Q3 2025: $1,940,764 — Increased from $1,544,081 in Q3 2024
• Net loss for nine months ended Sept 30, 2025: $1,424,436 — Decreased from $4,575,956 in the prior year
• Total net revenues for nine months ended Sept 30, 2025: $30,842,780 — Increased 12.4% from $27,432,376 in 2024
• Cash and cash equivalents as of Sept 30, 2025: $15,196,745 — Decreased from $17,964,184 at Dec 31, 2024
• Net cash used in financing activities for nine months ended Sept 30, 2025: $6,063,778 — Significant cash outflow
• Shares of common stock outstanding as of Nov 5, 2025: 14,956,627 — Increased from 13,952,624 shares at Dec 31, 2024
• Kristalose revenue for nine months ended Sept 30, 2025: $7,419,832 — Decreased from $10,935,702 in 2024
• Sancuso revenue for nine months ended Sept 30, 2025: $8,616,353 — Increased from $6,624,102 in 2024
• Vibativ revenue for nine months ended Sept 30, 2025: $6,678,374 — Increased from $5,087,983 in 2024
• Net cash provided by operating activities for nine months ended Sept 30, 2025: $4,929,498 — Improved from net cash used of $2,516,804 in 2024
• Net Loss for Q2 2025: $1.1M — Increased from $0.3M in Q2 2024
• Net Loss for H1 2025: $2.1M — Increased from $0.6M in H1 2024
• Total Revenues for Q2 2025: $9.5M — Decreased from $10.2M in Q2 2024
• Total Revenues for H1 2025: $19.0M — Decreased from $20.5M in H1 2024
• Kristalose Sales Q2 2025: $3.5M — Increased from $3.2M in Q2 2024

Related Companies

CPRX · CPix

Frequently Asked Questions